Cathie Wood Makes $64 Million Bet on Two Stocks
SC
Scribe Therapeutics Inc SCTX
$23.03
▲ +5.79%
(+$1.26)
🎈 Low Float
Open
$21.53
Prev Close
$21.77
Day Range
$21.29 – $23.75
52W Range
$17.31 – $39.60
Market Cap
$436.00M
Beta
-3.77
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| IPO Date | 2026-07-24 |
| Shares Out. | 17,580,000 |
| Website | scribetx.com ↗ |
| Phone | 19086427374 |
About Scribe Therapeutics Inc
Scribe Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of in vivo CRISPR-based genetic medicines. Its research and development activities focus on cardiovascular and metabolic diseases, including atherosclerotic cardiovascular disease (ASCVD). The company's product pipeline includes STX-1150, a CRISPR-based product candidate that utilizes its ELXR epigenetic silencing technology.
Scribe Therapeutics Inc is a publicly traded company under the ticker symbol SCTX on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
10 analysts (2026-09-01)
📰 Latest News for SCTX
Scribe Surges On IPO Debut -- But All Eyes Turn To 1H27 Data
Beyond Meta, Cathie Wood’s ARKG Loads Up On These 4 Biotech Names
Cathie Wood Loads Up On Biotech: 5 ETFs Holding Her Latest Bets
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gene-Editing Powerhouse And Its Rivals Surge Toward A Breakout